Closing the RBQM Adoption Gap: An AI-Guided Action Path from Risk Signals to Supervised Execution

“Clinical development does not lack visibility into operational risk. Risk-Based Quality Management has given study teams more dashboards, key risk indicators, and central monitoring signals than at any point in the industry’s history. What remains constrained is the capacity to translate those signals into timely, coordinated, and documented action across functions and systems.

This constraint is now a regulatory one. ICH E6(R3) Principles and Annex 1 reached final adoption in January 2025, became effective across the EU on July 23, 2025, and were published by the FDA in September 2025, with the MHRA and Health Canada following. RBQM is no longer encouraged practice – it is the operating model regulators expect across the trial lifecycle.

Yet adoption remains uneven, and the gap sits precisely where it matters most. Industry research from the Tufts Center for the Study of Drug Development, conducted with CluePoints and PwC across 206 respondents and 32 distinct RBQM components, found that organizations implement RBQM in 57% of clinical trials on average. Adoption is highest in documentation and resolution at 60% and lowest in execution at 52%. Smaller sponsors running fewer than 25 trials a year sit at 48%, against 63% at organizations running more than 100. The barriers identified are organizational rather than technical: limited cross-functional knowledge and awareness, mixed perceptions of the value proposition, and weak change management in planning and execution.

This is the RBQM adoption gap – the distance between regulatory expectation, demonstrated value, and what study teams can consistently operationalize. Clinical data professionals sit at its center. They surface the signals and document the decisions, but much of the supervisory work that should follow a signal still depends on manual coordination across sponsors, CROs, sites, and functional teams.

This session introduces the AI-guided action path: a structured approach for moving from risk signal to supervised, documented execution. Building on the clinical execution translation gap framework Maxis AI presented in June 2026, it applies the same principles to RBQM under ICH E6(R3). The discussion covers how a supervised AI Workforce can support triage, follow-up, escalation, reconciliation, and documentation of risk-based decisions while preserving human-in-the-loop validation, audit traceability, and alignment with regulated environments. The emphasis throughout is reliability and governance, not autonomy.

The session is designed for clinical data professionals navigating the evolution from Clinical Data Management to Clinical Data Science – the “Golden Era of Data” that defines SCDM’s 2026 agenda. Attendees will leave understanding where RBQM adoption stalls in execution, why monitoring and detection alone cannot close that gap, and how to evaluate where supervised execution capacity can be added to their own RBQM workflows without compromising oversight or audit defensibility.”

Key takeaways: 

• Where the RBQM adoption gap actually sits – benchmarked industry data on adoption across planning, execution, and documentation stages, and the organizational barriers driving the divergence between intent and execution
• Why monitoring and detection alone cannot close the gap – the distinction between identifying work and performing work, and what it takes to translate a risk signal into coordinated, documented, inspection-ready action
• What an AI-guided action path looks like in practice – how a supervised AI Workforce supports triage, follow-up, escalation, reconciliation, and documentation across clinical operations, data management, biometrics, and safety
• How human oversight and audit traceability are preserved – the human-in-the-loop validation, supervision thresholds, and logged execution history that align with ICH E6(R3) expectations for risk-proportionate quality management
• A practical way to evaluate readiness – how to identify which RBQM workflows in your own organization can be supported by supervised execution, and which require foundational process change first

Register now to explore how AI-guided action paths can help clinical trial teams move from RBQM risk signals to supervised, governed execution.